FIELD: medicine.
SUBSTANCE: invention claims method of virus infection treatment in case of main tissue damage and main virus replication point located in liver (versions), relevant kit and combination. Method involves combined injection of therapeutically effective amount of interferon and riboflavin, with riboflavin administered in slow-release composition in daily dosage under 400 mg to maintain clinically effective ribavirin level in portal vein blood stream and in lower amount than required to reach clinically effective level in peripheral circulation. Method maintains clinically effective interferon level in portal system blood stream, yet it is lower than in peripheral circulation, and therefore maintains systemic interferon effect on the whole organism and selective ribavirin action in liver. Kit and combination can include andioxidiser or other membrane-stabilising medium.
EFFECT: stable virological effect for patient, reduced side effects.
30 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF CYCLOSPORINE AND PEGYLATED INTERFERON COMBINATION FOR HEPATITIS (HCV) TREATMENT | 2005 |
|
RU2394589C2 |
| SILIBILIN COMPONENT FOR TREATING HEPATITIS | 2008 |
|
RU2482844C2 |
| USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
| METHOD OF TREATING CHRONIC VIRAL HEPATITIS C WITH MEDICATIONS IN LIPOSOMAL FORM | 2011 |
|
RU2475263C1 |
| METHOD OF TREATING VIRAL HEPATITIS C | 2012 |
|
RU2496512C1 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
| HCV-ACTIVE 4'-ASIDONUCLEOSIDES | 2011 |
|
RU2556991C2 |
| CCR5 ANTAGONIST FOR ENHANCING IMMUNORESTORATIVE THERAPY AND TREATMENT OF OPPORTUNISTIC INFECTION IN PATIENTS WITH HIV | 2007 |
|
RU2420284C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 ENABLING PREDICTION OF HCV TREATMENT RESPONSES | 2012 |
|
RU2606759C2 |
